- Home
- LFST vs CGON Comparison
LFST vs CGON Comparison
Compare LFST & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFST
- CGON
- Stock Information
- Founded
- LFST 2015
- CGON 2010
- Country
- LFST United States
- CGON United States
- Employees
- LFST N/A
- CGON N/A
- Industry
- LFST Medical/Nursing Services
- CGON
- Sector
- LFST Health Care
- CGON
- Exchange
- LFST Nasdaq
- CGON NYSE
- Market Cap
- LFST 1.9B
- CGON 2.1B
- IPO Year
- LFST 2021
- CGON 2024
- Fundamental
- Price
- LFST $5.17
- CGON $25.94
- Analyst Decision
- LFST Strong Buy
- CGON Strong Buy
- Analyst Count
- LFST 5
- CGON 10
- Target Price
- LFST $8.50
- CGON $64.44
- AVG Volume (30 Days)
- LFST 2.1M
- CGON 809.7K
- Earning Date
- LFST 08-07-2025
- CGON 08-07-2025
- Dividend Yield
- LFST N/A
- CGON N/A
- EPS Growth
- LFST N/A
- CGON N/A
- EPS
- LFST N/A
- CGON N/A
- Revenue
- LFST $1,283,503,000.00
- CGON $662,000.00
- Revenue This Year
- LFST $15.27
- CGON N/A
- Revenue Next Year
- LFST $13.94
- CGON $25,206.93
- P/E Ratio
- LFST N/A
- CGON N/A
- Revenue Growth
- LFST 16.31
- CGON 224.51
- 52 Week Low
- LFST $4.76
- CGON $14.80
- 52 Week High
- LFST $8.61
- CGON $40.47
- Technical
- Relative Strength Index (RSI)
- LFST 40.47
- CGON 50.40
- Support Level
- LFST $4.76
- CGON $25.24
- Resistance Level
- LFST $5.13
- CGON $26.59
- Average True Range (ATR)
- LFST 0.20
- CGON 1.10
- MACD
- LFST 0.01
- CGON -0.12
- Stochastic Oscillator
- LFST 35.32
- CGON 29.83
About LFST LifeStance Health Group Inc.
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family and group therapy. The group y has a single operating and reportable segment of mental health services.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.